Tetramethylpyrazine ferulate crystals for suppressing platelet aggregation and thrombosis and preparation method thereof
A technology of platelet aggregation and ferulic acid, which is applied in blood diseases, pharmaceutical formulations, organic active ingredients, etc., can solve the problem of not being able to provide a single pure crystal of ligustrazine ferulic acid, and achieve the effect of product toxicity and adverse reaction control
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment Construction
[0019] Mix Ligustrazine (tetramethylpyrazine) 2.8g and acetone 45mL, heat and stir to dissolve, then add ferulic acid 4.0g, reflux at 333K for 1 hour, filter and dry the reaction mixture after staying in the container for 5 days, and obtain the present invention Crystals, yellow crystals. Dissolve the yellow crystals in 45 mL of acetone, filter, vacuum-dry to half the volume of the filtrate, place on a clean crystallization bench, crystallize at room temperature, and crystallize for 6 hours to obtain ligustrazine ferulic acid monoclinic crystals. The crystal structure is monoclinic, and the space group is P2 1 / n, the cell parameters are: α=90°, β=93.654(6)°, γ=90°, the unit cell volume is
[0020] The following are the measured parameters of the crystal:
[0021] Instrument: X-ray crystal diffractometer Nova diffactometer Cu target: Nova X-ray source mirror
[0022] Scanning diffraction angle: unit cell 3.6-71.3°; atomic position 3.6-68.3°
[0023] Data processing...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


